N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis

N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Kasperzyk, J, d'Azzo, A, Platt, F, Seyfried, T
Μορφή:	Conference item
Έκδοση:	2004

Παρόμοια τεκμήρια

N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
ανά: Kasperzyk, J, κ.ά.
Έκδοση: (2004)

"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice" (vol 46, pg 744, 2004)
ανά: Kasperzyk, J, κ.ά.
Έκδοση: (2005)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
ανά: Baek, R, κ.ά.
Έκδοση: (2008)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
ανά: Baek, R, κ.ά.
Έκδοση: (2004)

Erratum: Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice (Journal of Lipid Research (April 2004) 46 (744-751))
ανά: Kasperzyk, J, κ.ά.
Έκδοση: (2005)

Substrate deprivation therapy reduces brain ganglioside content and GM1 in neonatal storage disease mice
ανά: Kasperzyk, J, κ.ά.
Έκδοση: (2002)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
ανά: Baek, R, κ.ά.
Έκδοση: (2005)

Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
ανά: Jeyakumar, M, κ.ά.
Έκδοση: (2003)

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
ανά: Elliot-Smith, E, κ.ά.
Έκδοση: (2008)

Therapeutic assessment of substrate deprivation using NB-DGJ in GM1 storage disease mice
ανά: Seyfried, T, κ.ά.
Έκδοση: (2003)

N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
ανά: Ranes, M, κ.ά.
Έκδοση: (2001)

Combined deficiencies of endosomal ganglioside neuraminidases 3 and 4 in mice cause lysosomal GM3 gangliosidosis
ανά: Pshezhetsky, A, κ.ά.
Έκδοση: (2017)

Combined deficiencies of endosomal ganglioside neuraminidases 3 and 4 in mice cause lysosomal GM3 gangliosidosis
ανά: Pshezhetsky, A, κ.ά.
Έκδοση: (2017)

Altered expression of ganglioside metabolizing enzymes results in GM3 ganglioside accumulation in cerebellar cells of a mouse model of juvenile neuronal ceroid lipofuscinosis
ανά: Somogyi, A, κ.ά.
Έκδοση: (2018)

Effects of substrate deprivation therapy on brain lipids in neonatal GML storage disease mice
ανά: Kasperzyk, J, κ.ά.
Έκδοση: (2003)

Therapeutic developments for neurodegenerative GM1 gangliosidosis
ανά: Dorian Foster, κ.ά.
Έκδοση: (2024-04-01)

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
ανά: Andersson, U, κ.ά.
Έκδοση: (2004)

GM1 Gangliosidosis Type 1 and Mongolian Spots
ανά: J Gordon Millichap
Έκδοση: (2013-06-01)

Altered GM1 catabolism affects NMDAR-mediated Ca2+ signaling at ER-PM junctions and increases synaptic spine formation in a GM1-gangliosidosis model
ανά: Jason A. Weesner, κ.ά.
Έκδοση: (2024-05-01)

GM1 ganglioside-independent intoxication by Cholera toxin
ανά: Cervin, J, κ.ά.
Έκδοση: (2018)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
ανά: Andersson, U, κ.ά.
Έκδοση: (2000)

Persistent elevations of alkaline phosphatase as an early indicator of GM1 gangliosidosis
ανά: Iskren Menkovic, κ.ά.
Έκδοση: (2025-03-01)

GM1 - gangliosidosis in a Nigerian infant: A case report
ανά: Abdullahi M Sakina, κ.ά.
Έκδοση: (2021-03-01)

Case report: Preimplantation genetic testing for infantile GM1 gangliosidosis
ανά: Valeria A. Zagaynova, κ.ά.
Έκδοση: (2024-02-01)

Genetic Analysis of Undiagnosed Juvenile GM1-Gangliosidosis by Microarray and Exome Sequencing
ανά: Ahmed Bouhouche, κ.ά.
Έκδοση: (2018-01-01)

GM2-gangliosidosis, type I (Tay – Sachs disease) in the pediatrician practice
ανά: Natalia V. Zhurkova, κ.ά.
Έκδοση: (2021-01-01)

Extensive telangiectasias and mongolian spots: A clue towards GM1-gangliosidosis
ανά: Sachin Gupta, κ.ά.
Έκδοση: (2023-01-01)

Elevation of ganglioside degradation pathway drives GM2 and GM3 within amyloid plaques in a transgenic mouse model of Alzheimer's disease
ανά: Wenxuan Wang, κ.ά.
Έκδοση: (2025-02-01)

Pathological findings of central nervous system, two GM1 gangliosidosis autopsy cases
ανά: Doğuş Özdemir Kara, κ.ά.
Έκδοση: (2019-12-01)

Clinical and imaging predictors of late‐onset GM2 gangliosidosis: A scoping review
ανά: Neha P. Godbole, κ.ά.
Έκδοση: (2024-01-01)

NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines
ανά: Luis E. Fernandez, κ.ά.
Έκδοση: (2010-01-01)

Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
ανά: Melanie Alpaugh, κ.ά.
Έκδοση: (2017-10-01)

GM2 Gangliosidosis (Tay-Sachs Disease), type I, Infantile Form: Clinical Case
ανά: Artem A. Babkin, κ.ά.
Έκδοση: (2024-09-01)

Re: “Molecular analysis of 9 unrelated families presenting with juvenile and chronic GM1 gangliosidosis”
ανά: Carlos Eduardo Steiner, κ.ά.
Έκδοση: (2024-02-01)

Mutations in B4GALNT1 (GM2 synthase) underlie a new disorder of ganglioside biosynthesis
ανά: Harlalka, G, κ.ά.
Έκδοση: (2013)

GM1 Ganglioside Promotes Osteogenic Differentiation of Human Tendon Stem Cells
ανά: Sonia Bergante, κ.ά.
Έκδοση: (2018-01-01)

Infantile Gangliosidosis
ανά: J Gordon Millichap
Έκδοση: (1988-08-01)

Quantitative reliability assessment of brain MRI volumetric measurements in type II GM1 gangliosidosis patients
ανά: Christopher Zoppo, κ.ά.
Έκδοση: (2024-09-01)

Enhanced Susceptibility to Chemoconvulsant-Induced Seizures in Ganglioside GM3 Synthase Knockout Mice
ανά: Fu-Lei Tang, κ.ά.
Έκδοση: (2020-07-01)

Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside
ανά: Julia Heinzelbecker, κ.ά.
Έκδοση: (2024-02-01)